1. Introduction
Candida bloodstream infections (CBSIs) are a leading cause of invasive fungal infections in hospitalized children, and one of the most common causes of healthcare-associated infections worldwide. While the epidemiology of invasive fungal infections, including CBSI, varies according to the geographical region and patient population, globally non-albicans Candida species together cause the majority of CBSI, and resistant Candida species and strains are emerging among adult patient populations.
While the CBSI incidence in children has been decreasing in the United States over recent decades [
1], as infection control and antimicrobial stewardship practices have continued to become more rigorous and universally implemented, CBSI still remain associated with high pathogen-related morbidity and mortality, increased length of hospitalization, and considerable resource utilization [
2,
3,
4]. Some pediatric patient populations such as neonates and infants under the age of one, children with hematologic malignancies, and critically ill children in intensive care units are known to be at increased risk for CBSI, but established risk factors remain poor predictors of when and in whom CBSI occur [
5]. Early diagnosis is especially challenging in children given the nonspecific symptoms of candidemia and the low sensitivity of blood cultures [
6]. In some populations, such as premature neonates and neutropenic oncologic patients, empiric or pre-emptive anti-fungal therapy can decrease delays to the initiation of the appropriate therapy inevitably caused by the reliance on blood culture results.
In adults, active surveillance studies in two US East Coast cities have shown significant declines in candidemia incidence and in central venous catheter-associated candidemia between 2008 and 2013 [
7]. In these studies, the predominant species were
C. albicans (36%) and
C. glabrata (27%) [
7]. Older single-center studies comparing adult candidemia patients over the years 1983–1986, 1997–2001, and 2004–2007 showed decreasing percentages of
C. albicans isolates from 61 to 47% over these periods and increasing percentages of
C. glabrata (from 0 to 29%), while
C. parapsilosis remained at 12% [
8]. In the
Candida isolates examined in that center over those periods, echinocandin resistance was not observed and the emergence of anti-fungal resistance was limited to 16% fluconazole resistant
C. glabrata in the last study period [
8]. However, pediatric and adult populations differ with respect to the prevalence of isolated
Candida species and susceptibility patterns even in the same geographic areas [
9,
10]. Therefore, the surveillance of local species distribution and anti-fungal susceptibility patterns aids in the rational choice of empiric or pre-emptive therapy for children, in choices of prophylactic regimens, and in antimicrobial stewardship. The present study was undertaken to evaluate changes in epidemiology, anti-fungal susceptibility, patient characteristics, and management of CBSI in a large freestanding children’s hospital over an 11-year period.
2. Materials and Methods
The Boston Children’s Hospital (BCH) Institutional Review Board approved protocol IRB-P00024287, “Retrospective Review of Candida Bloodstream Infections,” on 11/30/2016. We then performed a retrospective cohort study of CBSI in patients admitted to BCH between January 2006 and December 2016. Patients were identified from the database of the BCH clinical microbiology laboratory.
2.1. Study Site
Boston Children’s Hospital (BCH) is a 406-bed quaternary care children’s hospital in Boston, Massachusetts with specialized units including neonatal, cardiac, medical, and medical/surgical intensive care units, as well as oncology, solid organ, and stem cell transplant units, which care for highly complex patient populations.
2.2. Definitions
A CBSI was defined as a positive blood culture for a
Candida species alone. A CBSI episode was defined as a positive blood culture for only a
Candida species ≥30 days before or after another blood culture growing
Candida [
11]. Polymicrobial blood cultures growing other organisms in addition to
Candida species were not included. Breakthrough (BT)-CBSI was defined as a CBSI that occurred in patients receiving systemic anti-fungal agents for at least 3 days before the first positive blood culture [
12]. Central line-associated blood stream infection (CLABSI) was defined according to the Centers for Disease Control and Prevention (CDC) surveillance criteria [
13]. Recurrent CBSI was defined as a second or more episode of CBSI in the same patient, separated by at least 1 month. Patients were categorized as immunocompetent, immunocompromised, or in the neonatal intensive care unit (NICU). The latter group was considered separately due to the unique physiological immaturity of the neonatal immune system and skin barrier. Very preterm was defined as birth at less than 32 weeks of gestation and extremely preterm, defined as birth at or before 25 weeks of gestation. Mortality associated with CBSI was defined as death as a direct consequence of CBSI or death from CBSI-associated complications [
3], maximally 60 days after the first positive culture as determined by two investigators upon chart review (A.I.P. and J.R.K.).
Primary
Candida species identification was performed in the BCH microbiology laboratory. Blood samples were cultured in the BacT/AlerT 3D system (Biomérieux, Chicago, IL, USA). Positive culture bottles were plated on Sabouraud Dextrose Emmons (Becton Dickinson, Franklin Lakes, NJ, USA), in addition to bacteriologic agar media. Colonies growing on a Sabouraud medium were examined microscopically and yeast-shaped organisms were immediately inoculated to fetal bovine serum (Sigma Aldrich, St. Louis, MO, USA). Formation of germ tubes at 2.5–4 h confirmed speciation as
Candida albicans. Isolates that did not produce germ tubes were speciated by the VITEK 2YST card (Biomérieux) and/or by the API20 C AuX (Biomérieux) strip and confirmed by morphology on a cornmeal agar medium. Anti-fungal susceptibility testing was performed at ARUP Laboratories, Salt Lake City, Utah, USA, a commercial clinical laboratory. In vitro susceptibility to micafungin, fluconazole, and voriconazole was defined by Clinical and Laboratory Standards Institute criteria, as well as using species-specific epidemiological cutoff values for less prevalent
Candida species [
14]. Multi-resistance was defined as resistance to two anti-fungal drug classes, azoles and echinocandins.
A review of electronic medical records was performed on all patients within the study period with CBSI that met the study definitions. Relevant data collected from the electronic medical records included age, underlying disease, presence of neutropenia (neutrophil count <500/mm3), exposure to broad spectrum antibiotics (piperacillin-tazobactam, carbapenems, third and fourth generation cephalosporins, glycopeptides, aminoglycosides, and fluoroquinolones) in the 7 days preceding CBSI, exposure to systemic anti-fungals and steroids, and the anti-fungal agent used for the treatment when CBSI was identified. The presence of a central venous catheter (CVC) and receipt of parenteral nutrition (PN) at the time of CBSI were also recorded.
2.3. Outcome Measures and Statistical Analyses
Frequencies, percentages, and descriptive statistics were used to summarize patient characteristics and anti-fungal susceptibility overall, as well as by species of Candida causing CBSI. Differences in patient characteristics across species-specific CBSI were compared using the chi-square test of proportions for categorical variables and the Tukey’s multiple comparison test for distribution of the mean age of patients. The primary outcome was trends in the incidence rate of CBSI during the study period. Secondary outcomes included (1) age-specific trends in the incidence rate of CBSI, (2) risk factors for developing breakthrough-CBSI, and (3) risk factors associated with death. We calculated CBSI rates per 1000 patient days of hospitalization for each year in the study period, and Candida CLABSI rates per 1000 CVC days between 2011–2016, when data on CVC days became available. Additionally, we calculated annual CBSI rates per 1000 patient days by age group, using the following categories: Infants <1 year of age, children between ages of 1–4 years, and children >4 years of age. Annual trends in CBSI rates overall, Candida CLABSI rates, and CBSI rates by age group during the study period were evaluated using Poisson regression models. The secondary outcomes of breakthrough-CBSI and mortality were evaluated using multivariable logistic regression models. Odds ratios for relevant risk factors were first calculated using the univariate analysis and adjusted subsequently in multivariable models for age, gender, and other confounders. Risk factors in multivariable models were considered significant at a p-value of < 0.05. Analyses were conducted using SPSS version 26.0 (IBM, Armonk, New York, NY, USA).
4. Discussion
A number of pediatric studies have addressed specific aspects of the epidemiology, species distribution, anti-fungal susceptibility profiles, and treatment of CBSI, as well as outcome-associated factors [
2,
4,
12,
15,
16,
17,
18]. In our study, we reviewed these issues together from the neonatal period until young adulthood over more than a decade, providing an integrated view of trends in this infection.
The overall incidence rate of CBSI at this institution decreased by 62% over the 11-year period, consistent with similar trends reported by others [
7,
19,
20,
21]. The downward trend in CBSI predominated in younger children. Moreover, Cleveland et al. reported a decline in the crude incidence rate of CBSI in infants aged <1 year in the past two decades [
11].
Anti-fungal prophylaxis cannot explain the decline in incidence since routine anti-fungal prophylaxis in this pediatric hospital was limited to patients with cancer. We speculate that the observed CBSI decrease is multifactorial and includes a temporal trend of improved management of underlying diseases in surgery, oncology, and neonatology, as well as antimicrobial stewardship efforts. Since a Candida source is typically endogenous and may be less impacted by some infection control measures (e.g., healthcare worker hand hygiene or isolation precautions), preserving a balanced microbiome by reducing broad-spectrum antibiotic exposure whenever possible will likely favorably impact the CBSI risk.
Recent studies showed significant decreases in overall and
Candida-specific CLABSI [
22,
23,
24,
25]. In our series, the rate of
Candida CLABSI did not decrease in the observed half-decade for which CVC data were available, though the small annual sample sizes limit further conclusions. Measures to improve CVC care may affect
Candida CLABSI less than those caused by skin flora, given that they frequently arise from gastrointestinal translocation [
7]. Alternatively, achievable effects of rigorous catheter care and infection prevention may already have been maximized at the beginning of this half-decade. Similar to the others, we did not find a predominance of immunocompromised patients in CBSI [
4,
16]. However, a large majority of patients had chronic diseases and CVC.
Similar to the others, we found that non-
albicans Candida species, particularly
C. parapsilosis, now predominate in pediatric BSI [
4,
15,
16,
26,
27]. This contrasts with species distributions in adult patients. A recent survey of electronic medical records from 203 hospitals across the United States covering the years 2009–2017 for all patient age groups, identified 18,728 invasive candidiasis cases of 16,334 patients (among which 9839 cases represented candidemia) using microbiology laboratory data, as we did. Forty percent of the patients were >65 years old [
10], while 864 (5%) were <18 years of age [
10], suggesting that the findings of this large study are representative of adult candidiasis cases across the United States. Candidiasis incidence in this study was calculated by hospitalizations and not by patient years, as we did. Hence, a direct comparison with our results is not possible, but the downward trend of candidemia observed over the years of this study was not significant [
10]. While
Candida species distributions were not shown specifically for candidemia, overall 48% of isolates were
C. albicans, 24%
C. glabrata, 11%
C. parapsilosis, 7%
C. tropicalis, and 6% of isolates represented 26 other non-albicans species including
C. lusitaniae (10)
, highlighting the starkly different species distribution in our pediatric populations. Distinct host characteristics, less use of azole prophylaxis, and preferential administration of AmB over fluconazole to treat childhood CBSI may explain the discrepancy in
Candida species between adult and pediatric series [
28]. Liposomal AmB is tolerated in children much better than in adults, and its frequent use in our population may have limited emergence of anti-fungal-resistant species and strains, given the fitness defects of amphotericin-resistant
Candida [
29].
Of note,
C. lusitaniae was the third most common
Candida species causing BSI in our institution across the age groups. This species has rarely been reported previously as a cause of BSI and accounts for 1–2% of all non-
albicans Candida BSI across multiple studies [
4,
15,
16,
18,
26,
28,
30,
31,
32]. The use of polyenes has been associated with the selection of this species [
33], which can develop resistance to AmB during therapy. AmB monotherapy has been associated with a poor response especially in immunocompromised patients [
32,
34]. In our series, all tested
C. lusitaniae were susceptible to AmB, though susceptibilities were not obtained in 32% of the isolates.
C. lusitaniae has also been reported to be resistant to fluconazole, as two of our cases were. Therefore, anti-fungal susceptibilities of
C. lusitaniae isolates should be routinely tested, and recalcitrant infections should be re-examined for the development of resistance.
Anti-fungal resistance rates were extremely low in our study, with no signs of resistance emergence over the 11-year period, possibly related to the infrequent use of azole prophylaxis among our patients. Micafungin showed excellent activity against almost all
Candida isolates including
C. parapsilosis. Similar to other studies [
35], we found all
C. parapsilosis isolates to be susceptible to micafungin, and its use was not associated with clinical failure.
In children, mortality rates associated with CBSI have been reported between 9.3% and 37% [
2,
3,
4,
15,
17,
26]. Heterogeneity among studies, centers, and patient populations may explain the wide range of mortality in the literature. Mortality due to CBSI may be difficult to differentiate from that caused by the underlying illness even with propensity score analysis [
2,
36,
37]. Consistent with other reports [
30,
38], mortality in our institution did not improve over the 11-year period and was not related to anti-fungal resistance.
However, since 2012, CBSI-related mortality did not occur in children ≤4 years in our study. A low threshold for empiric AmB use in infants in our institution may have accounted for the improved prognosis in younger patients. AmB resistance in most
Candida species is extremely rare despite five decades of use. Moreover, strains that evolve AmB resistance exhibit diminished fitness and are less virulent [
29].
Notably, our experience differs from the findings of Ascher et al. [
39] that in neonates, lipid AmB formulations were associated with a higher mortality than the deoxycholate formulation. In that study, no distinction was made between three available lipid formulations of AmB, while in our hospital, only liposomal AmB (Ambisome) is used. The use of different liposomal amphotericin formulations between the neonatology centers included in the Ascher et al. study, in addition to specific center characteristics such as the prevalence of extreme prematurity, also may have influenced the observed mortality. Our findings support the use of liposomal AmB in neonates.
Our study has several important limitations. As a retrospective study from a single quaternary care pediatric hospital, the results may not be generalizable to children receiving care in other settings. Residual confounding from unmeasured factors, including severity of illness, is likely present and may influence associations between CBSI and mortality. More generally, identifying candidemia from blood culture data inevitably leads to a very significant undercount, given the low sensitivity of blood cultures for this infection of <50% [
40,
41]. This undercount currently affects all similar studies, while in the future, the routine use of next-generation sequencing as a molecular diagnostics tool could overcome this limitation.
In summary, we found a decreasing incidence rate of CBSI over time. C. parapsilosis and C. albicans BSI decreased, and CBSI-related mortality was absent after 2011 in younger children, resulting in an increased median age for CBSI and fatal cases over the 11-year period. Anti-fungal resistance was very low and did not increase over time. Microbiologic trends in pediatric CBSI differ from those in adults possibly since AmB use is rarely limited by toxicities in children. Further decreasing CBSI and improving their outcomes may require further improvements in the management of underlying comorbidities, including prematurity and malignancies, as well as improved diagnostics that permit treatment earlier in the infection course.